Citation
Devillier, Raynier, et al. "Poor Outcome With Nonmyeloablative Conditioning Regimen Before Cord Blood Transplantation for Patients With High-risk Acute Myeloid Leukemia Compared With Matched Related or Unrelated Donor Transplantation." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 20, no. 10, 2014, pp. 1560-5.
Devillier R, Harbi S, Fürst S, et al. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation. Biol Blood Marrow Transplant. 2014;20(10):1560-5.
Devillier, R., Harbi, S., Fürst, S., Crocchiolo, R., El-Cheikh, J., Castagna, L., Etienne, A., Calmels, B., Lemarie, C., Prebet, T., Granata, A., Charbonnier, A., Rey, J., Chabannon, C., Faucher, C., Vey, N., & Blaise, D. (2014). Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 20(10), 1560-5. https://doi.org/10.1016/j.bbmt.2014.06.006
Devillier R, et al. Poor Outcome With Nonmyeloablative Conditioning Regimen Before Cord Blood Transplantation for Patients With High-risk Acute Myeloid Leukemia Compared With Matched Related or Unrelated Donor Transplantation. Biol Blood Marrow Transplant. 2014;20(10):1560-5. PubMed PMID: 24933658.
TY - JOUR
T1 - Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
AU - Devillier,Raynier,
AU - Harbi,Samia,
AU - Fürst,Sabine,
AU - Crocchiolo,Roberto,
AU - El-Cheikh,Jean,
AU - Castagna,Luca,
AU - Etienne,Anne,
AU - Calmels,Boris,
AU - Lemarie,Claude,
AU - Prebet,Thomas,
AU - Granata,Angela,
AU - Charbonnier,Aude,
AU - Rey,Jérôme,
AU - Chabannon,Christian,
AU - Faucher,Catherine,
AU - Vey,Norbert,
AU - Blaise,Didier,
Y1 - 2014/06/14/
PY - 2014/05/05/received
PY - 2014/06/02/accepted
PY - 2014/6/17/entrez
PY - 2014/6/17/pubmed
PY - 2015/5/20/medline
KW - Acute myeloid leukemia
KW - Allogeneic hematopoietic stem cell transplantation
KW - Cord blood transplantation
KW - Reduced-intensity conditioning regimen
SP - 1560
EP - 5
JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
JO - Biol Blood Marrow Transplant
VL - 20
IS - 10
N2 - Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is recommended for patients with high-risk acute myeloid leukemia (AML). In many situations, a matched related (MRD) or matched unrelated donor (MUD) is lacking, in which case unrelated cord blood units (UCB) provide an alternative. We analyzed the outcome of consecutive high-risk AML patients prepared with reduced-intensity conditioning (RIC) regimens and allografted with UCB (n = 32) and compared their outcome with high-risk AML patients who underwent transplantation with MRD/MUD (n = 49) in the same period of time. Grade III to IV acute graft-versus-host disease (GVHD) occurred slightly more frequently in the UCB group (25%) than in the MRD/MUD group (8%) (P = .069). Conversely, we found a lower incidence of extensive chronic GVHD in the UCB group (6%) than in the MRD/MUD group (20%, P = .085). Nonrelapse mortality at 4 years was 16% and 22% in the UCB and MRD/MUD groups, respectively (P = .529). The cumulative incidence of relapse at 4 years was significantly higher in the UCB group (60%) than in the MRD/MUD group (27%, P = .006). Leukemia-free survival (LFS) and overall survival (OS) at 4 years were 25% and 34%, respectively, in the UCB group and 50% and 56%, respectively, in the MRD/MUD group (LFS, P = .029; OS, P = .072). Multivariate analyses adjusted by cytogenetics and disease status at the time of Allo-HSCT revealed that use of UCB remained an independent predictive factor of shorter LFS (hazard ratio, 2.0; 95% confidence interval, 1.1 to 3.6; P = .018), and was associated with a trend for shorter OS (hazard ratio, 1.7; 95% confidence interval, .9 to 3.2; P = .093). Whereas UCB provides an alternative for patients with high-risk AML lacking an MRD/MUD, the high incidence of relapse after RIC-based UCB Allo-HSCT is a concern. Attempts to improve leukemic control with UCB Allo-HSCT are warranted, as well as the evaluation of other alternative donors in this context.
SN - 1523-6536
UR - https://www.unboundmedicine.com/medline/citation/24933658/Poor_outcome_with_nonmyeloablative_conditioning_regimen_before_cord_blood_transplantation_for_patients_with_high_risk_acute_myeloid_leukemia_compared_with_matched_related_or_unrelated_donor_transplantation_
DB - PRIME
DP - Unbound Medicine
ER -